SubQperior™ Panel Screen

We perform in vivo panel screenings with subQperior^TM tumor models for efficacy testing of new IO drugs on a regular basis.

Screening new test substances on a panel of syngenic tumor models is useful for fast and economic efficacy testing of immune-modulating drugs, either as a single treatment or in combination with immune-checkpoint inhibitors. We offer 8 of our routine models of which clients can choose 6 models for screening, including CT26wt, CloneM3, 4T1, EMT6, MC38-CEA, B16-F10, RENCA, and LL-2. Vehicle and anti-PD1 treatment arms will be provided free of charge.

You pay for one group and receive results from three groups
Choose 6 out of 8 syngeneic tumor models
Executed with our high-performance subQperior tumor models for outstanding reproducible results

Contact an expert

Subscribe to our newsletter

Meet us at your next conference

Share

MuScreen for in vivo screen to evaluate immune modulating agents

Contact us to learn more

First name

Last name

Organization

Title

Email address

How did you hear about Reaction Biology?

Yes I'd like to learn more about SubQ screening service, please contact me

I have read the Data Protection Policy. I hereby consent to receiving marketing emails with information on existing and new services. I know that I can opt-out from receiving such emails at any time by contacting Reaction Biology at dataprotection@reactionbiology.de or by using the unsubscribe link which will be provided in each marketing email.

Leave this field blank

Find out about our options for immunophenotyping to get the most out of your screen here!

SubQperior™ Panel Screen

Contact us to learn more

Related Resources

Related Services